Submitted for Publication: June 5, 2012; final revision received June 29, 2012; accepted July 26, 2012.
Author Contributions: Drs Svrakic and Vambutas had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Svrakic, Pathak, and Vambutas. Acquisition of data: Svrakic, Pathak, Goldofsky, Hoffman, Chandrasekhar, Sperling, Alexiades, Ashbach, and Vambutas. Analysis and interpretation of data: Svrakic, Pathak, and Vambutas. Drafting of the manuscript: Svrakic, Ashbach, and Vambutas. Critical revision of the manuscript for important intellectual content: Pathak, Goldofsky, Hoffman, Chandrasekhar, Sperling, Alexiades, Ashbach, and Vambutas. Statistical analysis: Svrakic and Vambutas. Obtained funding: Vambutas. Administrative, technical, and material support: Pathak, Hoffman, Sperling, Ashbach, and Vambutas. Study supervision: Pathak and Vambutas.
Conflict of Interest Disclosures: Dr Chandrasekhar is a shareholder and board member of Scientific Development and Research Inc, a small biotech company involved in surfactant research. The Feinstein Institute for Medical Research is in the process of filing a patent for the measurement of TNF as a measure of steroid responsiveness in immune-mediated sensorineural hearing loss.
Funding/Support: This study was supported by a National Institutes of Health grants R21DC008894 and R21DC011827 (Dr Vambutas) and by the Merrill & Phoebe Goodman Otology Research Center.